Quick Answer
aTYR PHARMA INC reported Total Revenue of $190.0 thousand for fiscal year 2025.
aTYR PHARMA INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $190.0K -19.1% |
$235.0K -33.4% |
$353.0K -96.6% |
$10.39M | $0.00 -100.0% |
$10.46M +2377.5% |
| Revenue (ASC 606) | $190.0K -19.1% |
$235.0K -33.4% |
$353.0K -96.6% |
$10.39M | $0.00 -100.0% |
$10.46M +2377.5% |
| Net Income | -$74.12M -15.8% |
-$64.02M -27.1% |
-$50.39M -11.1% |
-$45.34M -34.3% |
-$33.77M -108.1% |
-$16.22M +0.0% |
| Diluted EPS | -$0.80 +7.0% |
-$0.86 +8.5% |
-$0.94 +41.3% |
-$1.60 +9.6% |
-$1.77 +0.0% |
-$1.77 |
| Total Assets | $93.00M -4.0% |
$96.83M -19.7% |
$120.65M +26.0% |
$95.79M -17.1% |
$115.54M +198.3% |
$38.73M +7.0% |
| Cash and Equivalents | $10.74M -2.8% |
$11.05M -51.0% |
$22.54M +125.9% |
$9.98M +327.3% |
$2.34M -86.2% |
$16.95M +84.1% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $67.48M -3.6% |
$70.02M -22.8% |
$90.66M +26.9% |
$71.46M -34.6% |
$109.30M +245.3% |
$31.65M +49.4% |
| R&D Expense | $60.22M +10.8% |
$54.37M +28.6% |
$42.29M -1.2% |
$42.81M +84.0% |
$23.26M +34.5% |
$17.29M +23.1% |
| Operating Income | -$77.63M -14.3% |
-$67.91M -23.7% |
-$54.92M -18.3% |
-$46.40M -36.4% |
-$34.02M -113.8% |
-$15.91M +30.8% |
| Shares Outstanding | 98.03M +16.6% |
84.04M +32.8% |
63.29M +114.5% |
29.50M +6.1% |
27.79M +152.2% |
11.02M +183.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $190.0K | — | — |
| Revenue (ASC 606) | September 30, 2025 | $190.0K | — | — |
| Net Income | September 30, 2025 | -$25.74M | -49.2% | -31.8% |
| Diluted EPS | September 30, 2025 | -$0.26 | -13.0% | -18.2% |
| Total Assets | September 30, 2025 | $106.65M | +16.4% | +5.0% |
| Cash and Equivalents | September 30, 2025 | $6.15M | -46.3% | -64.3% |
| Long-Term Debt | September 30, 2019 | $2.74M | -72.8% | -40.4% |
| Stockholders Equity | September 30, 2025 | $80.23M | +22.8% | +7.2% |
| R&D Expense | September 30, 2025 | $22.13M | +49.5% | +43.9% |
| Operating Income | September 30, 2025 | -$26.75M | -47.4% | -31.7% |
| Shares Outstanding | September 30, 2025 | 97.99M | +29.3% | +5.5% |
- aTYR PHARMA INC reported Total Revenue of $190.0 thousand for fiscal year 2025.
- aTYR PHARMA INC showed a decrease of -19.1% in Total Revenue compared to the prior fiscal year.
- aTYR PHARMA INC reported Revenue (ASC 606) of $190.0 thousand for fiscal year 2025.
- aTYR PHARMA INC showed a decrease of -19.1% in Revenue (ASC 606) compared to the prior fiscal year.
- aTYR PHARMA INC reported Net Income of -$74.12 million for fiscal year 2025.
- aTYR PHARMA INC showed a decrease of -15.8% in Net Income compared to the prior fiscal year.
- aTYR PHARMA INC reported Diluted EPS of $0.80 per share (loss) for fiscal year 2025.
- aTYR PHARMA INC showed an increase of +7.0% in Diluted EPS compared to the prior fiscal year.
- aTYR PHARMA INC reported Total Assets of $93.00 million for fiscal year 2025.
- aTYR PHARMA INC showed a decrease of -4.0% in Total Assets compared to the prior fiscal year.
- aTYR PHARMA INC reported Cash and Equivalents of $10.74 million for fiscal year 2025.
- aTYR PHARMA INC showed a decrease of -2.8% in Cash and Equivalents compared to the prior fiscal year.
- aTYR PHARMA INC reported Long-Term Debt of $8.26 million for fiscal year 2018.
- aTYR PHARMA INC showed a decrease of -43.9% in Long-Term Debt compared to the prior fiscal year.
- aTYR PHARMA INC reported Stockholders Equity of $67.48 million for fiscal year 2025.
- aTYR PHARMA INC showed a decrease of -3.6% in Stockholders Equity compared to the prior fiscal year.
- aTYR PHARMA INC reported R&D Expense of $60.22 million for fiscal year 2025.
- aTYR PHARMA INC showed an increase of +10.8% in R&D Expense compared to the prior fiscal year.
- aTYR PHARMA INC reported Operating Income of -$77.63 million for fiscal year 2025.
- aTYR PHARMA INC showed a decrease of -14.3% in Operating Income compared to the prior fiscal year.
- aTYR PHARMA INC reported Shares Outstanding of 98.03 million shares for fiscal year 2025.
- aTYR PHARMA INC showed an increase of +16.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: